Abstract
The new hepatobiliary contrast agent Mangan-DPDP, unlike extracellular Gd-DTPA, leads to a constant increase in signal intensity of normal liver tissue in MR imaging of the liver which lasts at least for 30 minutes. In 19 patients with malignant liver tumors there was no difference in the contrast between tumor and liver when using a dose of 5 or 10 mumol/kg. Contrast enhanced T1-w SE- and T1-w GE sequences show a significant increase in tumor/liver contrast compared with T1-weighted unenhanced sequences. This increase was also significant when compared with T2-w SE sequences. In 16% additional focal lesions were detected on the enhanced scan.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
English Abstract
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Contrast Media* / administration & dosage
-
Drug Evaluation
-
Edetic Acid / administration & dosage
-
Edetic Acid / analogs & derivatives*
-
Humans
-
Infusions, Intravenous
-
Liver / pathology
-
Liver Neoplasms / diagnosis*
-
Liver Neoplasms / secondary
-
Magnetic Resonance Imaging / instrumentation
-
Magnetic Resonance Imaging / methods*
-
Manganese* / administration & dosage
-
Middle Aged
-
Pyridoxal Phosphate / administration & dosage
-
Pyridoxal Phosphate / analogs & derivatives*
-
Sensitivity and Specificity
Substances
-
Contrast Media
-
Manganese
-
Pyridoxal Phosphate
-
Edetic Acid
-
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid